Is NBIX a Buy? What to Consider in 2026
Short answer
The bull case for Neurocrine Biosciences (NBIX) rests on Ingrezza is a durable, growing cash engine: Ingrezza net sales reached about $657 million in Q1 2026, up roughly 20 percent year over year on double-digit growth in new patient additions. Revenue (TTM) is ~$2.9 billion. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The dominant risk is concentration: Ingrezza still drives the majority of revenue, so any erosion from new VMAT2 competition, formulary or payer pressure, or pricing reform would hit results disproportionately. Whether NBIX is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Neurocrine Biosciences makes money primarily from Ingrezza (valbenazine), an oral VMAT2 inhibitor for tardive dyskinesia and chorea associated with Huntington's disease, which generated about $657 million in net product sales in Q1 2026, up roughly 20 percent year over year, with full-year 2026 guidance of about $2.7 to $2.8 billion. A second product, Crenessity (crinecerfont), launched for classic congenital adrenal hyperplasia and contributed about $153 million in Q1 2026, helping total quarterly revenue grow roughly 44 percent to about $815 million. The company is solidly profitable, reporting Q1 2026 net income near $198 million. Founded in 1992 and based in San Diego, Neurocrine spent years as a clinical-stage company before Ingrezza's 2017 approval turned it into a commercial neuroscience franchise. It has since built a pipeline spanning psychiatry and neurology, headlined by NBI-1117568, a selective muscarinic M4 agonist for schizophrenia that produced positive Phase 2 data and has entered a Phase 3 registrational program, plus additional muscarinic compounds licensed from Nxera Pharma. In 2026 the company also agreed to acquire Soleno Therapeutics for roughly $2.9 billion, broadening its rare-disease commercial portfolio.
What's the case for buying NBIX?
Ingrezza is a durable, growing cash engine
Ingrezza net sales reached about $657 million in Q1 2026, up roughly 20 percent year over year on double-digit growth in new patient additions. Management reaffirmed full-year 2026 guidance of about $2.7 to $2.8 billion. A large, still-underdiagnosed tardive dyskinesia population gives the franchise a long runway to fund the rest of the business.
Crenessity adds a real second product
Crenessity, the first non-glucocorticoid therapy for classic congenital adrenal hyperplasia, contributed about $153 million in Q1 2026, a fast ramp for a recent launch. Two-year data presented in 2026 showed sustained glucocorticoid dose reductions while maintaining hormone control. A genuine second franchise reduces reliance on a single drug.
Deep central nervous system pipeline
Neurocrine's pipeline spans psychiatry and neurology, led by NBI-1117568, a selective muscarinic M4 agonist that posted statistically significant Phase 2 schizophrenia data and entered a Phase 3 registrational program. Additional muscarinic compounds licensed from Nxera Pharma broaden the bet. Success in schizophrenia would open a large new market beyond movement disorders.
Profitable and self-funding
Unlike many biotechs, Neurocrine is consistently profitable, with Q1 2026 net income near $198 million and trailing-twelve-month revenue around $2.9 billion. That profitability lets it fund late-stage trials and acquisitions, such as the roughly $2.9 billion Soleno deal, without depending on dilutive financing during difficult market windows.
What are the risks to NBIX?
The dominant risk is concentration: Ingrezza still drives the majority of revenue, so any erosion from new VMAT2 competition, formulary or payer pressure, or pricing reform would hit results disproportionately. CNS drug development is also high-risk, and a single Phase 3 miss for the muscarinic program or other pipeline candidates could sharply reset expectations. Large acquisitions like Soleno add integration and execution risk, and the stock can be volatile around trial readouts, label decisions, and guidance updates.
How is NBIX valued? (as of 2026-06-27)
- Revenue (TTM): ~$2.9 billion
- Ingrezza net sales (Q1 2026): ~$657 million
- Crenessity net sales (Q1 2026): ~$153 million
- Net income (Q1 2026): ~$198 million
- P/E ratio (TTM): ~25x
- Market cap: ~$16 billion
Figures are approximate and tied to the asOf date, drawn from Q1 2026 results and mid-2026 market data. Neurocrine trades at a trailing P/E near 25x, a premium to the broader biotech group that reflects its profitability and pipeline optionality. Total Q1 2026 revenue grew about 44 percent year over year to roughly $815 million as Crenessity scaled alongside Ingrezza.
How do you decide if NBIX is a buy?
Rather than asking whether NBIX is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold NBIX indirectly through an index or sector ETF before adding more.
For the full picture, see the NBIX stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about NBIX against your real portfolio and see your actual exposure before deciding.
The bottom line on NBIX
The bottom line: Neurocrine Biosciences's story right now is Ingrezza is a durable, growing cash engine, with revenue (ttm) at ~$2.9 billion. If you believe that narrative continues, the call is about sizing NBIX sensibly and checking overlap with what you own; if you doubt it (the risk: the dominant risk is concentration: Ingrezza still drives the majority of revenue, so any erosion from new VMAT2 competition, formulary or payer pressure, or pricing reform would hit results disproportionately.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around NBIX with Walnut
Use Neurocrine Biosciences as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is NBIX a good stock to buy right now?
+
The case for Neurocrine Biosciences right now is Ingrezza is a durable, growing cash engine, with revenue (ttm) at ~$2.9 billion. If you believe that thesis holds, NBIX is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the dominant risk is concentration: Ingrezza still drives the majority of revenue, so any erosion from new VMAT2 competition, formulary or payer pressure, or pricing reform would hit results disproportionately. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Neurocrine Biosciences do?
+
Neurocrine Biosciences makes money primarily from Ingrezza (valbenazine), an oral VMAT2 inhibitor for tardive dyskinesia and chorea associated with Huntington's disease, which gene
What are the main risks of NBIX?
+
The dominant risk is concentration: Ingrezza still drives the majority of revenue, so any erosion from new VMAT2 competition, formulary or payer pressure, or pricing reform would hit results disproportionately. CNS drug development is also high-risk, and a single Phase 3 miss for the muscarinic program or other pipeline candidates could sharply reset expectations. Large acquisitions like Soleno add integration and execution risk, and the stock can be volatile around trial readouts, label decisions, and guidance updates.
Is NBIX a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is a profitable, cash-generating Ingrezza franchise funding a deep CNS pipeline and a second product in Crenessity. The bear case is heavy reliance on one drug plus binary trial risk. Weigh how it fits your overall portfolio rather than timing a single entry.
What does Neurocrine do?
+
Neurocrine Biosciences is a San Diego neuroscience biopharmaceutical company that develops and sells treatments for neurological, neuroendocrine, and psychiatric conditions. Its commercial products include Ingrezza for tardive dyskinesia and Crenessity for congenital adrenal hyperplasia, and it runs a pipeline spanning schizophrenia, depression, and other central nervous system disorders.
What is Ingrezza?
+
Ingrezza (valbenazine) is Neurocrine's flagship product, an oral VMAT2 inhibitor approved for tardive dyskinesia and for chorea associated with Huntington's disease. It is the company's largest revenue source, with about $657 million in net sales in Q1 2026 and full-year 2026 guidance of roughly $2.7 to $2.8 billion.
Does NBIX pay a dividend?
+
Neurocrine Biosciences does not currently pay a dividend. Like many growth-oriented biopharma companies, it reinvests profits into research, late-stage clinical trials, commercialization, and acquisitions such as the 2026 Soleno deal. Investors in NBIX are generally seeking potential share-price appreciation rather than dividend income.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell NBIX; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.